K.J. Harrison & Partners Inc Invests $621,000 in Gilead Sciences, Inc. (NASDAQ:GILD)

K.J. Harrison & Partners Inc bought a new position in shares of Gilead Sciences, Inc. (NASDAQ:GILD) in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund bought 7,665 shares of the biopharmaceutical company’s stock, valued at approximately $621,000.

Several other hedge funds and other institutional investors also recently made changes to their positions in the business. Callan Capital LLC bought a new stake in shares of Gilead Sciences during the fourth quarter worth about $375,000. Bryn Mawr Capital Management LLC purchased a new position in Gilead Sciences during the fourth quarter worth about $231,000. Motley Fool Asset Management LLC boosted its holdings in Gilead Sciences by 6.0% during the fourth quarter. Motley Fool Asset Management LLC now owns 37,509 shares of the biopharmaceutical company’s stock worth $3,039,000 after purchasing an additional 2,135 shares during the last quarter. Jackson Hole Capital Partners LLC boosted its holdings in Gilead Sciences by 6.8% during the fourth quarter. Jackson Hole Capital Partners LLC now owns 19,592 shares of the biopharmaceutical company’s stock worth $1,587,000 after purchasing an additional 1,241 shares during the last quarter. Finally, Bank Julius Baer & Co. Ltd Zurich boosted its holdings in Gilead Sciences by 3.0% during the fourth quarter. Bank Julius Baer & Co. Ltd Zurich now owns 429,936 shares of the biopharmaceutical company’s stock worth $34,829,000 after purchasing an additional 12,617 shares during the last quarter. 83.67% of the stock is owned by institutional investors.

Insider Buying and Selling at Gilead Sciences

In other Gilead Sciences news, insider Merdad Parsey sold 2,000 shares of the stock in a transaction on Monday, April 1st. The shares were sold at an average price of $72.96, for a total transaction of $145,920.00. Following the completion of the sale, the insider now owns 96,304 shares of the company’s stock, valued at approximately $7,026,339.84. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. 0.16% of the stock is currently owned by corporate insiders.

Gilead Sciences Trading Up 0.2 %

Shares of Gilead Sciences stock traded up $0.15 during trading on Friday, reaching $65.42. The company’s stock had a trading volume of 12,382,425 shares, compared to its average volume of 6,443,315. Gilead Sciences, Inc. has a 52-week low of $64.63 and a 52-week high of $87.86. The company has a market cap of $81.45 billion, a price-to-earnings ratio of 181.72, a PEG ratio of 1.17 and a beta of 0.19. The firm’s 50-day moving average is $71.28 and its two-hundred day moving average is $76.25. The company has a quick ratio of 1.27, a current ratio of 1.43 and a debt-to-equity ratio of 1.08.

Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings data on Thursday, April 25th. The biopharmaceutical company reported ($1.32) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.49) by $0.17. Gilead Sciences had a net margin of 1.76% and a return on equity of 23.08%. The company had revenue of $6.69 billion during the quarter, compared to analysts’ expectations of $6.36 billion. During the same quarter in the prior year, the company earned $1.37 EPS. The firm’s revenue was up 5.3% on a year-over-year basis. On average, sell-side analysts anticipate that Gilead Sciences, Inc. will post 4.2 earnings per share for the current year.

Gilead Sciences Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Thursday, June 27th. Shareholders of record on Friday, June 14th will be given a dividend of $0.77 per share. The ex-dividend date is Friday, June 14th. This represents a $3.08 annualized dividend and a yield of 4.71%. Gilead Sciences’s payout ratio is currently 855.56%.

Analyst Ratings Changes

Several research analysts recently weighed in on the stock. StockNews.com upgraded shares of Gilead Sciences from a “buy” rating to a “strong-buy” rating in a report on Saturday. Barclays dropped their target price on shares of Gilead Sciences from $85.00 to $80.00 and set an “equal weight” rating on the stock in a research note on Monday, February 12th. Truist Financial cut shares of Gilead Sciences from a “buy” rating to a “hold” rating and dropped their target price for the company from $91.00 to $82.00 in a research note on Thursday, February 22nd. Oppenheimer reiterated an “outperform” rating and issued a $105.00 target price on shares of Gilead Sciences in a research note on Friday, April 19th. Finally, Royal Bank of Canada dropped their target price on shares of Gilead Sciences from $76.00 to $74.00 and set a “sector perform” rating on the stock in a research note on Friday. Eleven equities research analysts have rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Hold” and a consensus target price of $83.87.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.